Background: Treatment of STEMI has considerably evolved over the past 2 decades. However, predictors of adverse events after STEMI are mostly based on early studies without consistent use of reperfusion therapy, P2Y12 inhibitors, and drug-eluting stent implantation. We aimed to identify predictors of adverse events among patients with ST-elevation myocardial infarction (STEMI) undergoing contemporary primary percutaneous coronary intervention (PCI). Methods: Individual data of 2655 patients from 2 primary PCI trials (EXAMINA-TION, N¼1504; COMFORTABLE-AMI, N¼1161) with identical endpoint definition and event adjudication were pooled. Predictors of patient-oriented (death or reinfarction) and device-oriented (definite stent thrombosis [ST] and target-lesion revascularization [TLR]) outcomes at 1 year were identified by multivariable Cox regressions analysis. Results: Killip class III/IV was the strongest predictor of death or reinfarction (OR5.11, 95%CI2.48-10.52), ST (OR7.74, 95%CI2.87-20.93), and any TLR (OR2.88, 95%CI1.17-7.06). Impaired LVEF (OR4.77, 95%CI2.10-10.82), final TIMI flow 0-2 (OR1.93, 95%CI1.05-3.54), hypertension (OR1.69, 95%CI1.11-2.59), age (OR1.68, 95%CI1.41-2.01), and peak CK (OR1.25, 95%CI1.02-1.54) were independent predictors of death or reinfarction. Allocation to treatment with DES was an independent predictor of a lower risk of ST (OR0.35, 95%CI0.16-0.74) and any TLR (OR0.34, 95%CI0.21-0.54).
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Conclusions: Killip class remains the strongest predictor of death or reinfarction among STEMI patients undergoing primary PCI. Noteworthy, DES use independently predicts a lower risk of TLR and definite ST. Background: Octogenarian represent a large part of ST-segment elevation myocardial infarction (STEMI) patients. The present study aimed at determine their characteristics, current management and prognosis. Methods: We analyzed data collected in the "ORBI" registry, a 6-years prospective registry of STEMI patients admitted within 24 hours of symptoms'onset to an interventional cardiology centre of Brittany (France). Main data about management, intra hospital outcome and prescription at discharge were compared between patients older (Group 1) and younger (Group 2) than 80, with a univariate analysis. We then calculated adjusted odds ratio for intra hospital mortality (group 1 vs group 2) when considering data about the patient, the delays and various aspect of revascularization. Results: Among 5000 patients included, 550 (11%, mean age 84.6AE3) constituted group 1, with a larger female prevalence (51 vs 20% in group 2, p<0.0001). Group 1 had a much longer median delay between onset of symptom and call for medical assistance (65 vs 45 min. in group 2, p<0.0001), and between admission and reperfusion (53 vs 45 min. in group 2, p¼0.01). Table 1 presents data about the management in both groups, both in the acute phase and at discharge. Group 1 had a significantly higher intra hospital mortality (16.5 vs 4.1% in group 2, p<0.0001). Moreover, the adjusted odd ratio for intra hospital mortality (group 1 vs group 2) was 2.73 [95% confidence limits 1.83-4.07], p<0.0001.
Conclusions: Octogenarian patients and more represent a large part of patients treated for STEMI, with significant differences in their presentation and management, and a higher intra hospital mortality. Moreover, this higher mortality rate persists after adjustment for patient characteristics, delays of coronary reperfusion, and management of revascularization. 
